NCT06560632View on ClinicalTrials.gov

Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 17, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2028

Conditions
Advanced Solid Tumor
Interventions
DRUG

RP-3467 at assigned dose and schedule

Eligible participants will be treated with escalating doses of RP-3467 monotherapy

DRUG

Olaparib 200-300 mg BID, daily

Eligible participants will be treated with escalating doses of RP-3467 in combination with Olaparib

Trial Locations (5)

10032

# 1008, Columbia University, New York

10065

# 1004, Memorial Sloan-Kettering Cancer Center, New York

63130

# 1011, The Washington University, St Louis

77030

# 1001, The University of Texas M.D. Anderson Cancer Center, Houston

94158

# 1025, The University of California, San Francisco

Sponsors
All Listed Sponsors
lead

Repare Therapeutics

INDUSTRY

NCT06560632 - Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter